Xalud Therapeutics is a biotechnology company developing a non-viral gene therapy platform to treat pathologic inflammation through immune modulation. The company is harnessing the power of interleukin-10 (IL-10), a potent cytokine that acts as a master regulator for multiple inflammatory pathways, to address the root cause of inflammation and subsequently restore homeostasis in the immune system. Xalud’s lead product candidate, XT-150, is a locally injectable plasmid DNA gene therapy expressing IL-10 to addresses pathologic inflammation and pain.
Location: United States, New York
Employees: 11-50
Total raised: $30M
Founded date: 2009
Investors 1
| Date | Name | Website |
| - | PBM Capita... | pbmcap.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 24.08.2021 | Series C | $30M | - |
Mentions in press and media 3
| Date | Title | Description |
| 31.08.2021 | Digital health news, funding roundup in the prior week; August 30 | Headspace's resilience brand and Ginger's clinical heft create mental health powerhouse Bambi Francisco Roizen sits down with Russ Glass, CEO of newly-formed Headspace Health, the combination of Ginger, a provider of on-demand coaching, the... |
| 25.08.2021 | Daily funding roundup - August 24th, 2021 | Bridge to Life raised $56M; Covera Health landed $25M; Equum Medical secured $20M Ramp: Ramp is a New York-based corporate card and expense management platform. Ramp has raised $300 million in Series C funding. Founders Fund led the round, ... |
| 24.08.2021 | Xalud Therapeutics : Completes Oversubscribed $30 Million Series C Financing | Xalud Therapeutics, a clinical-stage biotechnology company developing novel non-viral gene therapies to treat pathologic inflammation, announced today that it has raised $30 million in a Series C financing. “We are well positioned to contin... |